期刊文献+

Management of chronic hepatitis B before and after liver transplantation 被引量:4

Management of chronic hepatitis B before and after liver transplantation
下载PDF
导出
摘要 Liver transplantation remains the only curative option for eligible patients with complications of chronic hepatitis B(CHB) infection,including severe acute hepatitis flares,decompensated cirrhosis,and hepatocellular carcinoma. In general,all patients with CHB awaiting liver transplantation should be treated with oral nucleos(t)ide analogs(NAs) with high barriers to resistance to prevent potential flares of hepatitis and reduce disease progression. After liver transplantation,lifelong antiviral therapy is also required to prevent graft hepatitis,which may lead to subsequent graft loss. Although combination therapy using NA and hepatitis B immune globulin(HBIG) has been the regimen most widely adopted for over a decade,recent studies have demonstrated that newer NAs with low rates of resistance are effective in preventing graft hepatitis even without the use of HBIG,achieving excellent long term outcome. For patients without pre-existing resistant mutations,monotherapy with a single NA has been shown to be effective. For those with resistant strains,a combination of nucleoside analog and nucleotide analog should be used. To date,clinical trials using therapeutic vaccination have shown suboptimal response,as CHB patients likely have an immune deficit against HBV epitopes. Future strategies include targeting different sites of the hepatitis B replication cycle and restoring the host immunity response to facilitate complete viral eradication. Liver transplantation remains the only curative option foreligible patients with complications of chronic hepatitis B(CHB) infection, including severe acute hepatitis flares,decompensated cirrhosis, and hepatocellular carcinoma.In general, all patients with CHB awaiting liver transplantationshould be treated with oral nucleos(t)ideanalogs (NAs) with high barriers to resistance toprevent potential flares of hepatitis and reduce diseaseprogression. After liver transplantation, lifelong antiviraltherapy is also required to prevent graft hepatitis, whichmay lead to subsequent graft loss. Although combinationtherapy using NA and hepatitis B immune globulin(HBIG) has been the regimen most widely adopted forover a decade, recent studies have demonstrated thatnewer NAs with low rates of resistance are effective inpreventing graft hepatitis even without the use of HBIG,achieving excellent long term outcome. For patientswithout pre-existing resistant mutations, monotherapywith a single NA has been shown to be effective. Forthose with resistant strains, a combination of nucleosideanalog and nucleotide analog should be used. To date,clinical trials using therapeutic vaccination have shownsuboptimal response, as CHB patients likely have animmune deficit against HBV epitopes. Future strategiesinclude targeting different sites of the hepatitis Breplication cycle and restoring the host immunityresponse to facilitate complete viral eradication.
作者 James Fung
出处 《World Journal of Hepatology》 CAS 2015年第10期1421-1426,共6页 世界肝病学杂志(英文版)(电子版)
关键词 HEPATITIS B LIVER TRANSPLANTATION Antiviraltherapy PREVENTION PROPHYLAXIS HEPATITIS B immuneglobulin Hepatitis B Liver transplantation Antiviral therapy Prevention Prophylaxis Hepatitis B immune globulin
  • 相关文献

参考文献54

  • 1Yuen MF. Revisiting the natural history of chronic hepatitis B:impact of new concepts on clinical management. J GastroenterolHepatol 2007; 22: 973-976 [PMID: 17489961].
  • 2Fung J, Lai CL, Yuen MF. New paradigms for the treatment ofchronic hepatitis B. J Gastroenterol Hepatol 2008; 23: 1182-1192[PMID: 18637060].
  • 3Lok AS, McMahon BJ. Chronic hepatitis B: update 2009.Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190].
  • 4Liaw YF, Kao JH, Piravisuth T, Chan HLY, Chien RN, Liu CJ,Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, CooksleyG, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA,Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statementon the management of chronic hepatitis B: a 2012 update. HepatolInt 2012; 6: 531-561 [DOI: 10.1007/s12072-012-9365-4].
  • 5European Association For The Study Of The Liver. EASLClinical Practice Guidelines: management of chronic hepatitis B. JHepatol 2009; 50: 227-242 [PMID: 19054588].
  • 6Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U,Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment ofchronic hepatitis B with entecavir in patients with impaired liverfunction. Hepatology 2009; 50: 2001-2006 [PMID: 19937695DOI: 10.1002/hep.23346].
  • 7Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects ofnucleoside and nucleotide analogues in chronic hepatitis B treatment.J Gastroenterol Hepatol 2014; 29: 428-434 [PMID: 24372662 DOI:10.1111/jgh.12499].
  • 8Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, YuenJC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asianpatients: replicative level and risk of hepatocellular carcinoma.Gastroenterology 2008; 135: 1192-1199 [PMID: 18722377].
  • 9Seto WK, Tanaka Y, Wong DK, Lai CL, Shinkai N, Yuen JC, TongT, Fung J, Hung IF, Yuen MF. Evidence of serologic activity inchronic hepatitis B after surface antigen (HBsAg) seroclearancedocumented by conventional HBsAg assay. Hepatol Int 2012; 7:98-105 [PMID: 24014110 DOI: 10.1007/s12072-012-9354-7].
  • 10Umeda M, Marusawa H, Seno H, Katsurada A, Nabeshima M,Egawa H, Uemoto S, Inomata Y, Tanaka K, Chiba T. Hepatitis Bvirus infection in lymphatic tissues in inactive hepatitis B carriers.J Hepatol 2005; 42: 806-812 [PMID: 15885350 DOI: 10.1016/j.jhep.2005.01.016].

同被引文献14

引证文献4

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部